Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress

Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Biotech Stock (ATNM)
Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial

DelveInsight's analysts estimate that relapsed/refractory acute myeloid leukemia market is poised to show significant growth, mainly attributed to recent drug approvals, increasing incidence, and anticipated launch of novel therapies during the forecast period (2023–2032).

Time to pull up Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), on your screens now. Actinium Pharmaceuticals is dedicated to advancing targeted radiotherapies to significantly enhance survival outcomes for patients who have exhausted conventional cancer treatments. Among its leading candidates, Iomab-B is set to revolutionize the bone marrow transplant process for blood cancer treatment, while Actimab-A continues to show potential in pivotal trials for r/r AML. With over 230 patents in its portfolio, Actinium is also at the forefront of developing next-generation conditioning agents like Iomab-ACT to augment outcomes in cell and gene therapies, marking it as a leader in the oncology space.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a pioneer in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, recently shared significant findings from its Phase 3 SIERRA trial at the 2024 European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. This key trial focused on Iomab-B, a promising therapeutic agent for patients with relapsed or refractory acute myeloid leukemia (r/r AML).

The SIERRA trial, which targeted an older patient demographic (55 years and older) suffering from active r/r AML, enrolled 153 participants and provided critical insights into the efficacy of Iomab-B led bone marrow transplants (BMT). Notably, the trial's primary endpoint of durable complete remission was achieved exclusively by patients receiving Iomab-B led BMT, showcasing impressive survival rates: 92% at one year and 69% at two years, with significantly higher event-free survival.

Key Outcomes for Patients with TP53 Mutation

During the congress, Dr. Hannah Choe from Ohio State University, who is also a SIERRA trial investigator, presented compelling data regarding patients with the TP53 mutation, a genetic alteration associated with poor prognosis and limited treatment options. The data highlighted:

- A stark contrast in median Overall Survival (OS) between patients with TP53 mutations receiving Iomab-B (5.49 months) and those who did not (1.66 months), emphasizing Iomab-B's efficacy (hazard ratio=0.23, p=0.0002).

- Iomab-B's ability to improve outcomes even in TP53 negative patients, showcasing its potential to overcome detrimental genetic profiles.

Long-Term Efficacy Results

Further data presented revealed that 75% of patients on the Iomab-B arm achieved complete remission, compared to just 6.3% in the control arm. The durability of these remissions was underscored by a 22% durable complete remission rate in the Iomab-B arm, a significant statistic given the zero percent in the control group. Patients achieving durable complete remission also demonstrated remarkable survival rates, not reaching median overall survival yet.

Iomab-B was noted for its favorable safety profile, significantly reducing the risks of sepsis and mucositis compared to traditional care, further advocating its role as a safer and more effective treatment modality.

ATNM has a 52 week high of $10.24. According to, ATNM has average price target of $29.40 suggesting a significant upside potential from the current levels. 

Other biotech stocks to keep on top of radar include Biomarin Pharmaceuticals Inc. (NASDAQ: BMRN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Incyte Corporation (NASDAQ: INCY), Exelixis, Inc. (NASDAQ: EXEL), Mimedx Group, Inc. (NASDAQ: MDXG), Genmab AS (NASDAQ: GMAB), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Bio-Techne Corp (NASDAQ: TECH), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).


Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated five hundred dollars by a 3rd party Momentum Media LLC  for content distribution services on ATNM for June 17th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content.


Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.